Memorial Sloan-Kettering Cancer Center
High incidence of disease recurrence in brain and leptomeninges after gefitinib
Published in Mental Health Business Week, July 23rd, 2005
According to recent research published in the journal Cancer, "Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that induces an early and dramatic response in 10% of patients with advanced NSCLC. Long-term outcome and patterns of disease recurrence after response have not been described."
"The authors evaluated 139 patients with NSCLC treated with gefitinib at Memorial Sloan-Kettering Cancer Center between 1998 and 2002. They focused on patterns of disease...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week
More Articles from Mental Health Business Week
- Acadia Pharmaceuticals, Inc.
Positive interim results reported from phase II trial of Parkinson disease drug - Advanced Neuromodulation Systems, Inc.
Medical device firm expands market launch of neurostimulation system - Allon Therapeutics, Inc.
Allon files IND to begin clinical trials for second product AL-208 - Hythiam, Inc.
Hythiam expands licensing to Baltimore - The Scripps Research Institute
National institute awards grant to discover small molecule tools - Agency for Toxic Substances & Disease Registry
Human health research and policy development near Great Lakes described - More from this issue of Mental Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
